Omeros (OMER) Presents Positive Results from OMS721 Phase 2 in HSCT-TMA
Tweet Send to a Friend
Omeros Corporation (Nasdaq: OMER) announced that an abstract highlighting positive results from the ongoing OMS721 Phase 2 clinical trial in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
